uniQure NV
Fermé
44.72 1.08
Résumé
Variation du prix de l'action
24h
Min
44.19
Max
45
Revenu | -28M -81M |
|---|---|
Ventes | 2.3M 5.8M |
BPA | -1.22 |
Marge bénéficiaire | -1,387.759 |
Employés | 221 |
EBITDA | -34M -70M |
Prochains Résultats | 9 nov. 2026 |
|---|
Capitalisation Boursière | 460M 3.1B |
|---|---|
Ouverture précédente | 43.64 |
Clôture précédente | 44.72 |
uniQure NV Graphique
Les performances passées ne sont pas un indicateur fiable des résultats futurs.
Actualités Associées
Comparaison
Variation de prix
uniQure NV prévision
Éléments financiers
Frais Généraux et Administratifs
Dépenses d'exploitation
Résultat avant impôt
Ventes
Coût des ventes
Marge brute des ventes
Charges d'intérêt sur la dette
EBITDA
Bénéfice d'exploitation
$
À Propos uniQure NV
uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease. In addition, it is developing AMT-162, which is in preclinical trial for the treatment of superoxide dismutase 1- amyotrophic lateral sclerosis; AMT-260 that is in preclinical trial to treat temporal lobe epilepsy; AMT-191, which is in preclinical trial for the treatment of fabry disease; AMT-161 that is in preclinical trial to treat amyotrophic lateral sclerosis caused by mutations; AMT-240, which is in preclinical trial to for the treatment of autosomal dominant Alzheimer's disease; and AMT-210 that is in preclinical trial to treat Parkinson's disease. The company was founded in 1998 and is headquartered in Amsterdam, the Netherlands.